arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Matinas BioPharma Holdings, Inc.

MTNB
$0.18 0.00 (+1.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Matinas BioPharma Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.2M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -68.2% ↘
FCF / Share $-0.29 ↘
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-1.33M
↑ +74.7% —
FCF / Share Free cash flow per share
$-0.29
↓ -14.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Cash Quality →
47

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 56 quarters